Enhancement of Docosahexaenoic Acid and Eicosapentaenoic Acid Biosynthesis in Isochrysis galbana by Bacillus jeotgali
Marine Biotechnology · 2024
DOI: 10.1007/s10126-024-10337-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Biotechnology, 2024. Verfasst von Yijun Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Aquacultural Biotechnology Ministry of Education, Ningbo University, Ningbo, Zhejiang, 315832, China. Hauptthemen laut MEDLINE: Docosahexaenoic Acids, Eicosapentaenoic Acid, Haptophyta, Bacillus. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Ningbo Public Welfare Science and Technology Program, Natural Science Foundation of Ningbo Government, Zhejiang Provincial Department of Education Scientific Research Project.
Abstract (Originalsprache)
Isochrysis galbana is valuable in aquaculture due to its production of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). However, achieving high yields of polyunsaturated fatty acids (PUFAs) presents challenges, leading to exploration of innovative approaches. This study investigated the influence of Bacillus jeotgali on the growth of I. galbana and its fatty acid composition. Co-culturing I. galbana with B. jeotgali significantly increased chlorophyll a content and cell abundance, particularly at higher bacterial population densities (algae-to-bacteria ratio of 1:10). Physiological and biochemical analyses found elevated soluble protein content in microalgae co-cultured with B. jeotgali, accompanied by decreased superoxide dismutase (SOD) activity. Fatty acid composition analysis demonstrated a distinctive profile in co-cultured I. galbana, characterized by increased PUFAs, especially EPA and DHA. Gene expression analysis indicated an upregulation of desaturase genes (d4FAD, d5FAD, d6FAD, and d8FAD) associated with PUFA synthesis pathway in I. galbana during co-culturing with B. jeotgali. This study advances our understanding of bacteria-microalgae interactions and presents a promising strategy for enhancing the production of DHA and EPA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Aquacultural Biotechnology Ministry of Education, Ningbo University, Ningbo, Zhejiang, 315832, China.
- Key Laboratory of Aquacultural Biotechnology Ministry of Education, Ningbo University, Ningbo, Zhejiang, 315832, China. caojiayi@nbu.edu.cn.
- Collaborative Innovation Center for Zhejiang Marine High-Efficiency and Healthy Aquaculture, Ningbo University, Ningbo, Zhejiang, 315211, China.
- Ningbo Institute of Oceanography, Ningbo, Zhejiang, 315832, China.
- Key Laboratory of Aquacultural Biotechnology Ministry of Education, Ningbo University, Ningbo, Zhejiang, 315832, China. xujilin@nbu.edu.cn.
- Fujian Dalai Seed Science and Technology Co., Ltd., Ningde, Fujian, 352101, China. xujilin@nbu.edu.cn.
Förderung
- Ningbo Public Welfare Science and Technology Program
- Natural Science Foundation of Ningbo Government
- Zhejiang Provincial Department of Education Scientific Research Project
- Ningbo Science and Technology Research Projects, China
- the earmarked fund for CARS-49
Zitieren
APA
Xu, Y., Wu, M., Cao, J., Wang, Y., Zhang, L., Yan, X., Li, Y., & Xu, J. (2024). Enhancement of Docosahexaenoic Acid and Eicosapentaenoic Acid Biosynthesis in Isochrysis galbana by Bacillus jeotgali. Marine Biotechnology. https://doi.org/10.1007/s10126-024-10337-5
Vancouver
Xu Y, Wu M, Cao J, Wang Y, Zhang L, Yan X, et al. Enhancement of Docosahexaenoic Acid and Eicosapentaenoic Acid Biosynthesis in Isochrysis galbana by Bacillus jeotgali. Marine Biotechnology. 2024. doi:10.1007/s10126-024-10337-5
BibTeX
@article{Xu2024,
author = {Xu, Yijun and Wu, Minnan and Cao, Jiayi and Wang, Yingying and Zhang, Lin and Yan, Xiaojun and Li, Yanrong and Xu, Jilin},
title = {Enhancement of Docosahexaenoic Acid and Eicosapentaenoic Acid Biosynthesis in Isochrysis galbana by Bacillus jeotgali},
journal = {Marine Biotechnology},
year = {2024},
doi = {10.1007/s10126-024-10337-5}
}
EUVIMED